Atazanavir (Reyataz)

Overview | News | Research

Overvew

Prescribing Information for Atazanavir (Reyataz) (PDF) (January 2013)
From Bristol-Myers Squibb Company
Dose-Ranging, Randomized, Clinical Trial of Atazanavir With Lamivudine and Stavudine in Antiretroviral-Naive Subjects: 48-Week Results
In AIDS
Frequently Asked Questions About Atazanavir (Reyataz) (January 25, 2012)
Questions asked by patients at the Ask the Experts Forum at Body.com.
From The Body's "Ask the Experts" Forums
Atazanavir (Reyataz) Package Insert Revisions (January 16, 2008)
From U.S. Food and Drug Administration
Labeling Changes for Atazanavir (Reyataz) (January 26, 2006)
To read PDF, click here.
From U.S. Food and Drug Administration
HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From TheBodyPRO.com
Position Paper on Atazanavir (BMS-232623, Reyataz) (July 23, 2003)
In TAGline, from Treatment Action Group
Atazanavir Briefing Document (PDF) (May 2003)
Submitted to the FDA in advance of its May 13 Antiviral Drugs Advisory Committee meeting.
From Bristol-Myers Squibb Company
FDA Review Document: Reyataz (Atazanavir Sulfate) Capsules and Powder for Oral Use (April 14, 2003)
To read PDF, click here.
From U.S. Food and Drug Administration
HIV JournalView: It's Official: Once-Daily Atazanavir Effective in Naive Patients (September 2004)
From TheBodyPRO.com

News & Research

Clinical Trials Using Atazanavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Recent Changes to the Reyataz (Atazanavir Sulfate) Capsule Labeling (February 8, 2013)
From U.S. Food and Drug Administration
New Public-Private Partnership Will Allow Brazil to Produce Patented Antiretroviral for National Treatment Program (December 7, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors (November 18, 2012)
From Journal Watch
Reyataz and Kidney Stones (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
HIV JournalView: September 2012 (October 15, 2012)
David Alain Wohl, M.D., explores recently published findings regarding access to HIV care in the U.S., the impact of pain on clinic no-shows, links between atazanavir and gall/kidney stones, anal sex and HIV among women, and the limits of echocardiography.
In HIV JournalView, from TheBodyPRO.com
Maraviroc Plus Atazanavir/Ritonavir in a Nuke-Sparing Regimen in Treatment-Naive Patients (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
First Report: Atazanavir-Related Gallstones (Cholelithiasis) (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Once-Daily Maraviroc + Boosted Atazanavir Looks Promising at 96 Weeks (July 25, 2012)
From HIVandHepatitis.com
Once-Daily Maraviroc Plus Boosted Atazanavir Promising at 96 Weeks (July 25, 2012)
From aidsmap.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.